Clinical trials: Birch Pollen Allergy
Allergic Rhinitis, Allergic Rhinoconjunctivitis
SUBLIVAC FIX Birch Dose Tolerability/Dose Range Finding
The aim of the study is to determine the optimal effective dose of SUBLIVAC FIX Birch based on reduction of upper airways reactivity after 5 months of treatment with different dosages of SUBLIVAC FIX Birch compared to placebo.
- Trial name
- NCT01639768
- Testing
- SUBLIVAC FIX Birch
- Where
- 20 sites in Czechia, Germany and 1 more
- Volunteers
- 270 people
- Sponsor
- HAL Allergy
Type I Hypersensitivity
Different Doses of Tyrosine Adsorbed Tree Pollen Allergoid With Monophosphoryl Lipid A (MPL) in Patients Sensitized to Tree Pollen
Allergen-specific immunotherapy (SIT), the administration of gradually increasing quantities of an allergen extract to an allergic patient, is a curative approach which directly treats the underlying allergic disease.
- Trial name
- NCT00118612
- Testing
- Tree MATA MPL - Therapeutic Regimen, Tree MATA MPL - Intermediate dose, Tree MATA MPL - Low dose
- Where
- Canada
- Volunteers
- 68 people
- Sponsor
- Allergy Therapeutics
Type I Hypersensitivity
Investigation of Efficacy and Safety of Tree MATAMPL,Tree MATA, and Placebo in Patients With Birch-Induced Seasonal Allergic Rhinitis
Tree MATAMPL has been developed to provide pre-seasonal specific immunotherapy for patients with hypersensitivity to Tree (birch, alder, hazel) pollen (hay fever).
- Trial name
- NCT00387478
- Testing
- Tree MATA MPL or Tree MATA
- Where
- Canada
- Volunteers
- 121 people
- Sponsor
- Allergy Therapeutics
Type I Hypersensitivity
Assessment of the Contribution of Monophosphoryl Lipid A (MPL) to a Tree Pollen Allergy Vaccine
Allergen-specific immunotherapy (SIT), the administration of gradually increasing quantities of an allergen extract to an allergic patient, is a curative approach which directly treats the underlying allergic disease.
- Trial name
- NCT00118625
- Testing
- Tree MATA MPL
- Where
- Canada
- Volunteers
- 40 people
- Sponsor
- Allergy Therapeutics
Birch Pollen Allergy
Safety, Tolerability And Pharmacodynamics of DM-101PX in Birch Pollen Allergy
Randomized, double-blind placebo-controlled phase I trial with the primary aim to investigate safety and tolerability of DM-101-PX compared to placebo in birch pollen allergic adults.
- Trial name
- UPSIT (NCT07898800)
- Testing
- DM-101PX
- Where
- Germany
- Volunteers
- 40 people
- Sponsor
- Desentum Oy
Allergy
Efficacy and Safety of Subcutaneous Immunotherapy in Birch Pollen Allergic Patients
To compare versus placebo the efficacy and safety of recombinant Bet v1, natural purified Bet v1 and birch pollen licenced extract used for subcutaneous immunotherapy.
- Trial name
- NCT00410930
- Testing
- Subcutaneous immunotherapy - Recombinant birch pollen
- Where
- France
- Volunteers
- 160 people
- Sponsor
- Stallergenes Greer
Birch Pollen Induced Rhinitis/Rhinoconjunctivitis
SUBLIVAC FIX Birch Phase III Short-term Efficacy
The aim of this phase III study is to asses if SUBLIVAC FIX Birch is safe and effective in reducing birch allergy induced symptoms and birch allergy medication usage.
- Trial name
- NCT02231307
- Testing
- SUBLIVAC FIX Birch
- Where
- 40 sites in Belgium, Czechia and 3 more
- Volunteers
- 406 people
- Sponsor
- HAL Allergy
Allergy
A Study in Children and Adolescents With Birch Pollen-induced Rhinoconjunctivitis
This is a clinical study in children and adolescents (5-17 years) with allergy to pollen from birch (or related trees). It compares the tree SLIT-tablet with placebo in relieving rhinoconjunctivitis symptoms during the birch/tree…
- Trial name
- TreeTop (NCT04878354)
- Testing
- Tree SLIT-tablet
- Where
- 80 sites in Austria, Belgium and 9 more
- Volunteers
- 952 people
- Sponsor
- ALK-Abelló A/S
Allergic Rhinitis, Rhinoconjunctivitis
Efficacy Study of a Preseasonal Treatment With AllerT in Subjects With Birch Pollen Allergy
The main objective of the trial is to demonstrate the efficacy of a two months pre-seasonal treatment with AllerT 100 µg maintenance dose in reducing symptoms of allergic rhinoconjunctivitis during the following birch pollen…
- Trial name
- NCT01720251
- Testing
- AllerT low dose, AllerT full dose
- Where
- 24 sites in Denmark, France and 5 more
- Volunteers
- 240 people
- Sponsor
- Anergis
Birch Pollen-related Rhinoconjunctivitis, Rhinitis, Allergic, Seasonal
Study of rBet v1 Tablets
The purpose of this study is to determine the efficacy and safety of three doses of r Bet v1 administered as sublingual tablets in birch pollen allergic subjects.
- Trial name
- NCT00901914
- Testing
- rBet v 1
- Where
- 8 sites in Denmark, Finland and 6 more
- Volunteers
- 483 people
- Sponsor
- Stallergenes Greer
Allergic Rhinitis, Allergy to Pollen
Evaluation of the Nasal and Conjunctival Response in Subjects Allergic to Birch Pollen in the ALYATEC Environmental Exposure Chamber
The aim of this study is to assess the nasal and conjunctival response in subjects allergic to birch pollen during controlled exposures in the ALYATEC environmental exposure chamber (EEC)
- Conditions
- Allergic Rhinitis, Allergy to Pollen, Rhinoconjunctivitis
- Trial name
- NCT04583202
- Testing
- Exposure to allergen
- Where
- France
- Volunteers
- 30 people
- Sponsor
- Alyatec
Birch Pollen Allergy
Specific Immunotherapy With Recombinant Birch Pollen Allergen rBet v1-FV
Specific immunotherapy with recombinant birch pollen allergen rBet v1-FV
- Trial name
- NCT00266526
- Testing
- Recombinant birch pollen
- Where
- Germany
- Sponsor
- Allergopharma GmbH & Co. KG
Hypersensitivity, Allergic Rhinitis
Efficacy and Safety Study of a Sublingual Immunotherapy Solution to Treat Patients Suffering From Birch Pollen Allergic Rhinoconjunctivitis
The purpose of this 2-year study is to assess the sustained clinical efficacy and safety of 300 IR/day of a sublingual solution of birch pollen allergen extract starting 4 months prior to the birch pollen season and continuing…
- Conditions
- Hypersensitivity, Allergic Rhinitis, Allergic Conjunctivitis, Seasonal Allergy
- Trial name
- NCT01731249
- Testing
- Birch pollen allergen extract
- Where
- 11 sites in Czechia, Denmark and 9 more
- Volunteers
- 574 people
- Sponsor
- Stallergenes Greer
Birch Pollen Allergy
Safety and Efficacy of Recombinant Birch Pollen Allergen in the Treatment of Allergic Rhinoconjunctivitis
Safety and efficacy of recombinant birch pollen allergen in the treatment of allergic rhinoconjunctivitis
- Trial name
- NCT00309062
- Testing
- Recombinant birch pollen
- Where
- Germany
- Sponsor
- Allergopharma GmbH & Co. KG
Allergy
Biological Standardization of Allergen Extracts of Pollens of Betula Pendula, Phleum Pratense and Mite Extract of Dermatophagoides Pteronyssinus
Allergen extracts are complex mixtures of proteins and contain varying amounts of allergenic and non-allergenic components. Many factors such as the biovariability, differences in extraction process and subsequent handling of…
- Trial name
- NCT01147159
- Testing
- Extracts of allergens
- Where
- Switzerland
- Volunteers
- 68 people
- Sponsor
- Roxall Medicina España S.A
Allergy
Sensitivity and Specificity of 3 Solutions of Allergen Extract for Diagnosis by Skin Prick Testing
A Phase III study to determine the sensitivity and specificity of three solutions of different allergen extracts for diagnosis by skin prick-test: 5 Grasses pollen, Birch pollen, Dermatophagoides pteronyssinus mite
- Trial name
- NCT01964768
- Testing
- Skin prick-test
- Volunteers
- 324 people
- Sponsor
- Stallergenes Greer
Allergic Rhinoconjunctivitis
Immunological and Histological Evaluation of Specific Immunotherapy With Recombinant Hypoallergenic Derivative
This trial is performed for the immunological and histological evaluation of specific immunotherapy with an aluminium hydroxide-adsorbed recombinant hypoallergenic derivative of the major birch pollen allergen, rBet v1-FV
- Trial name
- NCT00841516
- Testing
- rBet v1-FV
- Where
- Sweden
- Volunteers
- 14 people
- Sponsor
- Allergopharma GmbH & Co. KG
Allergic Conjunctivitis
Clinical Validation Study in Allergic Conjunctivitis to Birch Pollen During Allergen Challenge in ALYATEC EEC
This is a single center open study designed to determine the concentration of airborne birch pollen inducing an allergic conjunctivitis response in individuals allergic to birch pollen, during allergen exposures in the Alyatec…
- Trial name
- NCT04641130
- Testing
- Exposure to birch pollen in EEC
- Where
- France
- Volunteers
- 16 people
- Sponsor
- Alyatec
Rhinoconjunctivitis
Open Label Safety Study of a Birch Pollen Allergen Extract
This trial is performed to assess safety of a sublingual birch pollen extract.
- Trial name
- NCT00818181
- Testing
- Biological: AL0206st
- Where
- Germany
- Volunteers
- 73 people
- Sponsor
- Allergopharma GmbH & Co. KG
Birch Pollen-Related Rhinoconjunctivitis, Rhinitis, Allergic, Seasonal
Safety, Tolerability and Pharmacodynamic Effects of Sublingual Immunotherapy (Tablets) With Recombinant Bet v1
To investigate the safety and tolerability of successive single rising doses of SLIT in subjects with allergic rhinitis and to investigate the safety and tolerability of multi high dose regimens of SLIT in subjects with allergic…
- Trial name
- NCT00396149
- Testing
- rBet v 1
- Where
- Denmark
- Volunteers
- 57 people
- Sponsor
- Stallergenes Greer